Veterinary Medicines

FILAVAC MYX L JF613 SUSPENSION A DILUER ET SOLVANT POUR SUSPENSION INJECTABLE POUR LAPINS

Authorised
This information is not available for this product.
Download as PDF

Product identification

Medicine name:
FILAVAC MYX L JF613 SUSPENSION A DILUER ET SOLVANT POUR SUSPENSION INJECTABLE POUR LAPINS
Active substance:
This information is not available for this product.
Target species:
  • Rabbit
  • Rabbit (for reproduction)
Route of administration:
  • Intradermal use

Product details

Active substance and strength:
This information is not available for this product.
Pharmaceutical form:
  • Suspension and solvent for suspension for injection
Withdrawal period by route of administration:
  • Intradermal use
    • Rabbit
      • All relevant tissues
        0
        day
    • Rabbit (for reproduction)
      • All relevant tissues
        0
        day
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QI08AD02
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • France
Package description:

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Full application - New active substance (Article 12(3) of Directive No 2001/82/EC)
Marketing authorisation holder:
  • Filavie
Marketing authorisation date:
Manufacturing sites for batch release:
  • Filavie
Responsible authority:
  • French Agency For Food, Environmental And Occupational Health & Safety
Authorisation number:
  • FR/V/9660163 5/2018
Date of authorisation status change:

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.
French (PDF)
Published on: 25/01/2023
Download
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."